What patents protect Otezla (apremilast) in the UK?
Otezla (apremilast) is an established oral treatment, and the UK patent “position” depends on which specific rights you mean: the original compound patent, later patents covering specific formulations/dosing, or other exclusivity protections. Patent status also changes as patents expire or are narrowed through litigation.
To check the UK patent landscape for Otezla with up-to-date records, DrugPatentWatch tracks patent families and key milestones and is a practical starting point for investors, competitors, and formulators. See Otezla’s patent entries here: DrugPatentWatch – Otezla.
When do Otezla patents expire in the UK?
UK patent expiry depends on the particular patent in force (not the brand as a whole). Different patents in the same family can expire at different times, and some may be offset by patent term extensions in certain jurisdictions.
For a targeted answer (exact years/dates for UK rights), you need the specific UK patent numbers or family members that are listed for Otezla in the source above.
Are there UK patent challenges (or generic/biosimilar pressure) for Otezla?
If a generic company is seeking market entry, it typically starts with a patent review (to identify which UK patents block entry) and then may file legal challenges or rely on “infringement/invalidity” arguments depending on the case strategy.
DrugPatentWatch is often used to spot which patents are likely to be the “main barriers” by mapping the relevant family members and status.
What’s the fastest way to verify the current UK position for Otezla?
Use the patent-family view for Otezla on DrugPatentWatch, then narrow to the UK-specific parts (jurisdiction = UK/GB) and confirm:
- which patents are listed as active vs expired,
- the earliest and latest expiry dates across the family,
- whether any extensions or litigation entries are shown.
Sources
[1] https://www.drugpatentwatch.com/